Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

188 results about "CARCINOMA LIVER" patented technology

Malignant or cancerous cells that develop in the normal cells of the liver (hepatocytes) are called hepatocellular carcinoma. A cancer that arises in the ducts of the liver is called cholangiocarcinoma.

Dimer compound of guaiane type sesquiterpenes and uric acid as well as extraction and separation method and application of dimer compound

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.
Owner:KUNMING MEDICAL UNIVERSITY +1

Hepatoma carcinoma cell ablation system based on steep pulse

The invention relates to the technical field of medical instruments, and provides a steep pulse-based ablation system and method for liver cancer cells, and the system comprises a tumor feature recognition module which is used for obtaining imaging images of the liver cancer cells and recognizing tumor features, blood supply conditions and tumor centers of the liver cancer cells; the electrode inlet setting module is used for setting a safety boundary of liver cancer cells and setting an ablation area and a focus skin surface of the liver cancer cells based on the safety boundary and tumor characteristics; the ablation effect analysis module is used for calculating the electrode depth and the electrode angle of the liver cancer cells and analyzing the coverage effect of an ablation area; the electric field intensity identification module is used for analyzing cell membrane characteristics of the hepatoma cells, identifying the electroporation effect of the hepatoma cells and identifying the electric field intensity of the hepatoma cells; and the steep pulse ablation module is used for performing ablation treatment on the liver cancer cells in combination with the electric field intensity and a pulse generator to obtain an ablation result. The invention aims to avoid heat injury of surrounding tissues and improve the ablation effect of liver cancer cells.
Owner:TIANJIN YINGTAI LIANKANG MEDICAL SCI & TECH CO LTD +1

Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody

A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.
Owner:LEAP THERAPEUTICS INC

Method of liver cancer treatment with safranal-based formulations

Methods of treating, suppressing, or reducing the severity of a liver cancer in a subject are described herein. The disclosed methods involve administering a therapeutically effective amount of a composition including safranal or its pharmaceutically acceptable pro-drug, and a pharmaceutically acceptable carrier to the subject. The disclosed methods may be used to treat, suppress, or reduce the severity of various liver cancers, including hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, a metastatic liver cancer, and combinations thereof.
Owner:UNITED ARAB EMIRATES UNIVERSITY

Liver cancer segmentation system and method based on deep learning

The invention provides a liver cancer segmentation system and method based on deep learning. A dual-cavity convolution module extracts features of an input image; the attention module introduces a channel attention mechanism, extracts context information of the feature map by using average pooling and convolution operation, and generates an attention map according to the context; the big kernel attention gate module respectively performs convolution processing on the feature maps output by the encoder and the decoder, and combines high-level features with low-level features to obtain an enhanced feature map; the down-sampling module is used for carrying out average pooling and maximum pooling on the input feature maps respectively, and splicing the feature maps; the up-sampling module is used for generating a dynamic offset from the input feature map to obtain a coordinate after dynamic offset, and sampling on dynamic interpolation is carried out; the polarized multi-scale feature self-attention module carries out resolution integration and channel attention and space attention calculation on an input image in sequence. And the hepatocellular carcinoma area can be accurately segmented, so that a doctor can be effectively assisted to diagnose and treat liver cancer.
Owner:CHONGQING UNIV

Culture medium and method for constructing liver cancer or bile duct cancer explant and application

The invention belongs to the technical field of biological medicine, and particularly relates to a culture medium and method for constructing a liver cancer or bile duct cancer explant and application. According to the culture medium and the method for constructing the liver cancer or cholangiocarcinoma explant, tumor tissues cut by a liver cancer patient through an operation are utilized, an optimized explant culture medium is utilized for multiplication culture, and a liver cancer explant model with high activity and a complete structure can be constructed through construction of an explant culture method; the method can be used for screening and guiding drugs.
Owner:SHENYANG KANGWEI MEDICAL LAB CO LTD

Liver cancer metastasis risk prediction method and system based on image-pathomics feature fusion

The invention discloses a liver cancer metastasis risk prediction method and system based on image-pathomics feature fusion, and relates to the technical field of medical information intelligent processing, and the method comprises the following steps: 1, carrying out the collection and preprocessing of multi-modal data; step 2, image omics feature extraction; step 3, extracting pathological omics features; 4, performing feature screening and fusion modeling; 5, constructing and verifying a risk prediction model; and step 6, outputting and visualizing a result. The method aims at solving the problems that in existing liver cancer metastasis risk prediction, information utilization is single, images and pathological features are not fused, and prediction accuracy is insufficient. At present, clinical assessment mainly depends on pathological grading, AFP and other indexes, and cannot reflect tumor intrinsic heterogeneity, resulting in inaccurate metastasis risk prediction. According to the invention, the image omics-pathomics combined feature fusion prediction model and system are established, and multi-modal data automatic processing, feature optimization and individualized risk assessment are realized.
Owner:JIAMUSI UNIVERSITY +1

Novel polypeptide, polypeptide derivative and use thereof

PCT designated stage expiredWO2025031513A1Peptide-nucleic acidsAntibody mimetics/scaffoldsJejunal TumorNeuroblastoma
Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and / or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD

Hybrid cell membrane modified nano-drug for inhibiting interment of macrophages as well as preparation method and application of nano-drug

The invention provides a preparation method of a hybrid cell membrane modified nano-drug for inhibiting interment of macrophages. According to the invention, a multifunctional bionic nano-drug with a'core-shell 'structure is prepared from liver cancer cell membrane and bone marrow-derived macrophage membrane hybrid double-drug-loading carrier nanoparticles. In the application, the bionic function of macrophages is firstly realized, so that the drug is prevented from being swallowed by mononuclear macrophages in vivo, and the side effect of the drug is reduced; secondly, by utilizing the homologous targeting effect of hepatoma carcinoma cells of Hepa1-6, the aggregation of the medicine in tumors is enhanced, and the utilization efficiency of the medicine is improved; finally, the two drugs including sorafenib and Xkr8siRNA are co-delivered, so that the pharmacokinetics is simplified, and the immunotherapy effect of the liver cancer can be promoted by utilizing the inhibition of the Xkr8siRNA on the intercellular effect.
Owner:THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY

Generation method for surgical resection-type sufficient radiation therapy dose plan for large hepatocellular carcinoma

The present invention provides a generation method for a surgical resection-type sufficient radiation therapy dose plan for a large hepatocellular carcinoma. Assuming the principles of liver segmentectomy or hemihepatectomy principles when surgical liver resection is used to resect a liver tumor, a radiation therapy plan is generated using a liver region volume remaining after the assumed surgical resection as a target. The method specifically comprises: step 1, obtaining an original medical image; step 2, identifying a target region, a maximal dose region, and a remaining liver region from the original medical image, and obtaining a region identification result; step 3, obtaining a remaining liver region volume, and determining whether the remaining liver region volume is within a preset range; if the remaining liver region volume is not within the preset range, ending; otherwise, executing step 4; step 4, performing radiation therapy plan design on the basis of the region identification result and the original medical image, and obtaining a radiation therapy plan result. The maximum value of the preset range is 700 ml, and the minimum value is 300 ml. The present method can automatically implement radiation therapy plan generation.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Compositions and methods for inhibiting carp-1 binding to nemo

PendingUS20250257058A1Organic chemistryAntineoplastic agentsGastrointestinal cancerChronic myeloproliferative disorders
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1

Methods of treating cancer by administering a neoadjuvant PD-1 inhibitor

The present disclosure provides methods for treating, reducing the severity of, inhibiting the growth of a tumor, or inducing necrosis of a tumor, wherein the method includes selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or abioequivalent thereof) as neoadjuvant therapy followed by surgical resection and optional administration of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof) as post-surgery adjuvant therapy. In certain embodiments, the liver cancer is hepatocellular carcinoma (HCC), the lung cancer is non-small cell lung cancer (NSCLC), or the head and neck cancer is head and neck squamous cell carcinoma (HNSCC).
Owner:REGENERON PHARMACEUTICALS INC

DNA methylation biomarker for liver cancer detection and application of DNA methylation biomarker

The invention provides a DNA methylation biomarker for liver cancer detection and application of the DNA methylation biomarker, and belongs to the technical field of biology. The biomarker disclosed by the invention is selected from any one of the following methylation sites: cg13597025, cg00033450, cg20335273, cg06121113, cg27629428, cg02307184, cg15602112 and cg26472334, and the biomarker disclosed by the invention can be used for detecting the methylation sites of the cg13597025 and the cg00033450. The biomarker provided by the invention can be used for noninvasive detection of liver cancer, and has important significance for early screening of liver cancer.
Owner:SHANGHAI SHANGSHI DONGTAN SANATORIUM CO LTD

Application of copper carrier in medicine for enhancing drug resistance of copper death reversing liver cancer cells

The invention discloses application of a copper carrier in a medicine for enhancing drug resistance of copper death reversing liver cancer cells, and relates to the technical field of medicines. The copper carrier provided by the invention can activate copper death in cisplatin-resistant liver cancer cells in a manner of'three-arrow simultaneous shooting '. The method mainly comprises the following steps: increasing the number of copper ions entering cells (a first'arrow '), consuming GSH to reduce the loss of copper ions in the cells (a second'arrow'), and down-regulating the expression of ATP7B to inhibit the outflow of copper ions (a third'arrow '). Besides, the copper carrier down-regulates copper death related proteins (FDX1, DLAT, ATP7B and LIAS), also down-regulates drug resistance related proteins (ATP7B and P-gp), and shows a remarkable anti-liver cancer curative effect. Particularly, the bCCM can target mitochondria, improve the mitochondrial copper ion level, consume mitochondrial GSH and cause mitochondrial dysfunction mediated by copper death, and the bCCM and the cis-platinum have a remarkable synergistic effect and can reverse the drug resistance of the cis-platinum.
Owner:HUNAN UNIV OF CHINESE MEDICINE

Liver cancer detection reagent based on OTX1

The invention belongs to the field of gene diagnosis, and particularly relates to a liver cancer detection reagent based on OTX1. The reagent comprises a detection reagent for OTX1 gene methylation, and the detection reagent is used for detecting the modified sequence of the OTX1 gene. Experiments prove that the detection reagent disclosed by the invention can detect and diagnose liver cancer with high sensitivity and high specificity, and has extremely high clinical application value.
Owner:CREATIVE BIOSCIENCES (GUANGZHOU) CO LTD

5-aldehyde heterocyclic amide compounds and their applications

The present invention relates to a 5-formyl heterocyclic amide compound and its application. The compound has a compound of formula (I) structure or a pharmaceutically acceptable salt, stereoisomer and prodrug molecule thereof. The compound of the present invention has FGFR4 inhibitory activity and can be used to prevent or treat diseases with abnormal FGFR4 activity such as fusion or overexpression, such as liver cancer, bile duct cancer, breast cancer, gastric cancer, prostate cancer, etc., and can also be used in combination with other drugs to be applied in anti-tumor and anti-cancer drugs.
Owner:JINAN UNIVERSITY +1

Methods of treating cancer by administering combination therapy comprising a neoadjuvant PD-1 inhibitor

This disclosure provides methods for treating tumors, reducing tumor severity, inhibiting tumor growth, or inducing tumor necrosis, wherein the methods include: selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need of treatment and administering neoadjuvant therapy to the patient in a combination of a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) and radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fenpromab), followed by surgical resection and optionally administration of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) as postoperative adjuvant therapy. In some embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).
Owner:REGENERON PHARMACEUTICALS INC

OTC mRNA nucleic acid medicine for treating hepatic fibrosis and hepatocellular carcinoma and application of OTC mRNA nucleic acid medicine

The invention provides an mRNA nucleic acid medicine and application thereof. The mRNA comprises a nucleic acid with a nucleotide sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 3. The mRNA can be used for treating hepatic fibrosis, relieving clinical hepatic fibrosis, inhibiting the progress of hepatic fibrosis, promoting liver cancer cells to differentiate into hepatic cells with partial liver functions, recovering the liver functions and prolonging the survival time of HCC patients.
Owner:CHINA PHARM UNIV

Traditional Chinese medicine preparation for treating liver cancer

The invention provides a traditional Chinese medicine preparation for treating liver cancer, and relates to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared from radix fici simplicissimae, euphorbia helioscopia, herba ardisiae japonicae, pollen typhae, ginseng, radix gentianae macrophyllae, cortex eucommiae, citrus aurantium, sambucus chinensis, hypericum japonicum and fructus ziziphi jujubae. In the formula, radix fici simplicissimae and euphorbia helioscopia are used as monarch drugs, herba ardisiae japonicae, pollen typhae, ginseng and gentiana macrophylla are used as ministerial drugs, citrus aurantium, sambucus chinensis, hypericum japonicum and eucommia ulmoides are used as adjuvant drugs, Chinese dates are used as conductant drugs, and the medicines in the whole formula are reasonably matched in monarch, ministerial, adjuvant and conductant drugs, give consideration to body resistance strengthening and evil eliminating, and jointly achieve the effects of tonifying qi, strengthening body resistance, dispersing blood stasis, detoxifying, clearing heat, promoting diuresis, soothing liver and regulating qi. The traditional Chinese medicine preparation has a remarkable inhibiting effect on proliferation, migration and invasion of hepatoma carcinoma cells, can effectively reduce the tumor volume and weight of tumor-bearing mice, slows down the tumor growth speed, can effectively improve the immune organ index and immune cell factors of the tumor-bearing mice, has an immunological enhancement effect, and can be used for treating liver cancer. The traditional Chinese medicine preparation is expected to serve as a new choice of medicines for treating liver cancer.
Owner:HENAN UNIV OF CHINESE MEDICINE

Cynanchum atratum extract as well as preparation method and application thereof

The invention discloses a cynanchum atratum extract as well as a preparation method and application thereof. The cynanchum atratum extract is an extract obtained by extracting cynanchum atratum with 50-80% ethanol. The cynanchum atratum is a root and a rhizome of a Tylophora yunnanensis Schlechter, which is a plant of the Schlechter family, and the root and the rhizome of the Tylophora yunnanensis Schlechter. Cell experiments and animal experiments prove that the extract obtained by extracting cynanchum atratum with 75% ethanol has the effects of inhibiting breast cancer and hepatoma carcinoma cell proliferation, inducing breast cancer and hepatoma carcinoma cell death and reducing tumor volume and tumor quality, has a remarkable effect on treating liver cancer and breast cancer, and has a practical application value.
Owner:HUAIBEI NORMAL UNIVERSITY

Liver-cancer-related serum microrna marker and new method for diagnosing liver cancer

PCT designated stage expiredWO2025035595A1Microbiological testing/measurementDNA/RNA fragmentationSerum micrornaChronic hepatitis
Provided in the present invention are a liver-cancer-related serum microRNA marker and a new method for diagnosing liver cancer. The liver-cancer-related serum microRNA marker is composed of hsa-miR-122, hsa-miR-21, hsa-miR-2115, hsa-miR-221, hsa-miR-27 and hsa-miR-4499. The relative expression level of each liver-cancer-related serum microRNA marker in serum is detected by means of a real-time PCR method, and the detection reagent comprises primers of the above-described liver-cancer-related serum microRNA markers. The present invention can be used for diagnosing hepatocellular carcinoma, especially early hepatocellular carcinoma; or for distinguishing serum of at least one hepatocellular carcinoma patient from serum of at least one healthy individual, serum of at least one chronic hepatitis B patient or serum of at least one liver cirrhosis patient.
Owner:QINGDAO RUISIDE MEDICAL LABORATORY CO LTD

MXene compound coated with cancer cell membrane and loaded with STING agonist as well as preparation method and application of MXene compound

The invention discloses a cancer cell membrane coated STING agonist loaded MXene compound and a preparation method and application thereof, and belongs to the technical field of biomedical materials.The preparation method comprises the steps that Ti3AlC2 and LiF are mixed, a concentrated hydrochloric acid solution is added, a reaction is conducted for 24-72 h at the temperature of 25-50 DEG C, and then centrifugal washing is conducted to obtain a black precipitate; adding the black precipitate into water, carrying out ultrasonic treatment under the protection of nitrogen to obtain a colloidal solution, and then centrifugally collecting supernate to obtain a d-MXene solution; the preparation method comprises the following steps: mixing a d-MXene solution and an STING agonist solution, stirring at room temperature, reacting in a dark place, adding a micromolecule enhancer containing an amide group into the mixture during the reaction to obtain an STING agonist-loaded MXene compound, and further coating by using a liver cancer cell membrane to obtain a cancer cell membrane-coated STING agonist-loaded MXene compound. The compound has a wide application prospect in the aspect of hepatocellular carcinoma treatment.
Owner:THE FOURTH AFFILIATED HOSPITAL OF ZHEJIANG UNIV SCHOOL OF MEDICINE

Anti-human tim3 antibodies for in vitro diagnostics

The disclosure provides binding agents (e.g., antibodies) against a human Hepatitis A virus cellular receptor 2 protein (TIM3), as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting Non-Small Cell Lung Cancer (NSCLC) and / or other types of lung cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) or other types of liver cancer, Renal cell carcinoma, malignant melanoma, gastro-intestinal cancer, colorectal cancer, urothelial carcinoma and other types of bladder cancer, mamma carcinoma and / or other types of breast cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, lymphoma / leukemia, malignant mesothelioma, or a cancer in another organ or cell type.
Owner:AGILENT TECHNOLOGIES INC

Application of miR-30a-5p and target gene thereof in diagnosis and treatment of hepatocellular carcinoma

The invention discloses application of miR-30a-5p and a target gene thereof in diagnosis and treatment of hepatocellular carcinoma, according to the scheme, tests prove that the toxic and side effects of an anti-hepatocellular carcinoma drug 5-fluorouracil can be remarkably reduced by reducing the expression quantity of miR-30a-5p, so that miR-30a-5p becomes a potential target for screening drugs for reducing the toxic and side effects of 5-fluorouracil; and when the target gene Thbs2 of the miR-30a-5p is in low expression, immunohistochemical (IHC) staining data is further retrieved from an HPA database, and the expression level of the Thbs2 obtained from the perspective of protein is medium in staining in normal liver tissues and relatively high in staining in liver cancer tissues, so that the Thbs2 can be used as a molecular marker for liver cancer diagnosis. The research provides an important basis for clinical early diagnosis and differential diagnosis of liver cancer and effective observation and alleviation of side effects of anti-cancer drugs, provides a brand new idea for accurate diagnosis of liver cancer and alleviation of side effects of anti-cancer drugs from the molecular level, and expands the cognition of the occurrence and development mechanism of liver cancer in the theoretical level. The obvious practical value and transformation potential are also shown in clinical application.
Owner:FUJIAN AGRI & FORESTRY UNIV

Annonaceous acetogenin compound and application thereof

PendingCN120208901ADigestive systemOrganic chemistry methodsAnnona montanaAnnona squamosa
The invention relates to a drug combination of annona squamosa lactone compounds and sorafenib (SF), which is characterized in that four common human hepatoma cell lines HepG2, HuH7, MHCC97H and HCCLM3 are used as research objects, and the drug combination effect among different components is evaluated by using an MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 3-diphenyltetrazolium bromide) method and Synergy Finder software. The combination of the compound and SF shows an obvious synergistic inhibition effect on the growth of hepatoma carcinoma cells, and meanwhile, the pharmaceutical composition can synergistically reduce the ATP level of the hepatoma carcinoma cells and induce hepatoma carcinoma cell apoptosis. Pharmacodynamic experiments show that the compounds annonacin and SF can synergistically inhibit tumor growth and induce tumor cell apoptosis, and have no obvious toxicity to normal organs of nude mice at a low dosage. In addition, transcriptome analysis predicts that the anti-liver cancer target of the annonacin is possibly related to the SLC33A1 gene. The method can be used for preparing anti-hepatoma drugs and researching related mechanisms. The annona lactone compound disclosed by the invention is derived from annona montana Macf. Which is an annona plant, namely annona montana Macf.
Owner:FUDAN UNIVERSITY

Thaflavin as UGP2 inhibitor and application of theaflavin in preparation of medicine for preventing and / or treating hepatocellular carcinoma

The invention relates to application of theaflavin as a UGP2 inhibitor and application of theaflavin in preparation of a medicine for preventing and / or treating hepatocellular carcinoma, and belongs to the technical field of biology. According to the invention, the monomeric compound theaflavin derived from a natural product can be used as a UGP2 direct targeting inhibitor for the first time, and is used for preparing a liver cancer treatment medicine for regulating and controlling glucose metabolism reprogramming. The theaflavin can be specifically and directly combined at a UGP2 active site in a targeting manner through high activity to inhibit the activity of the UGP2, is the first specific inhibitor which takes the UGP2 as a target spot and is reported at present, and can be used for remarkably inhibiting tumor phenotypes such as proliferation, migration and invasion of liver cancer cells by inhibiting UGP2-mediated UDPG synthesis and intracellular glycogen accumulation.
Owner:SHENYANG PHARMA UNIV

A method for inhibiting expression of receptor tyrosine kinase EPHA2 and application of RNA

A method for inhibiting expression of receptor tyrosine kinase EPHA2, which comprises inhibiting expression of receptor tyrosine kinase EPHA2 of tumor cells by regulating expression of a ubiquitin ligase RNF114, and the mode of regulating the ubiquitin ligase RNF114 comprises knocking down expression level of RNF114 protein by RNA interference technology, or knocking out RNF114 protein expression gene by CRISPR / Cas9 method. The present application uses biochemical and tumor molecular biology means to study ubiquitination of receptor tyrosine kinase EPHA2 regulated by ubiquitin ligase RNF114 and its role in proliferation and migration of hepatocarcinoma cells. Meanwhile, the present application effectively knocks down or knocks out expression of RNF114 in hepatocarcinoma cells by designing specific siRNA, shRNA and sgRNA, and finds that the proliferation and migration ability of hepatocarcinoma cells can be effectively inhibited.
Owner:SHAOXING RES INST OF ZHEJIANG UNIV

Application of a derivative of hypocrellin with amino substitution or ethylenediamine substitution at the 2-position in the preparation of an anti-tumor photodynamic drug

The present invention relates to a 2-amino-substituted derivative (Formula I) or an ethylenediamine-substituted derivative (Formulas II and III) of hypocrellin as a photodynamic drug for treating the following tumors: esophageal cancer, gastric cancer, lung cancer, liver cancer, cholangiocarcinoma, colon cancer cells related to digestive tract tumors; brain cancer, head and neck cancer, tongue cancer, nasal cancer, oral cancer, glioblastoma cells related to head, neck and facial tumors; basal cell carcinoma, squamous cell carcinoma, cutaneous T-cell lymphoma, melanoma cells related to skin tumors; prostate cancer, bladder cancer cells related to genitourinary tumors. At the same time, such derivatives can localize the location of tumor tissues through their own fluorescence and are used for fluorescence-guided surgical resection of tumors.
Owner:TECHNICAL INST OF PHYSICS & CHEMISTRY - CHINESE ACAD OF SCI

Application of ZNF710 gene in preparation of preparation for hepatocellular carcinoma diagnosis and / or prognosis evaluation

The invention relates to the technical field of biological medicines, in particular to application of a ZNF710 gene in preparation of a preparation for hepatocellular carcinoma diagnosis and / or prognosis evaluation. The invention finds and verifies that ZNF710 is closely related to prognosis of liver cancer for the first time and is a key gene for occurrence and development of tumors, and patients with low expression of the ZNF710 gene have higher survival rate. Therefore, compared with the prior art, a novel liver cancer diagnosis and treatment scheme taking the ZNF710 gene as the molecular marker has relatively high clinical application value and potential.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Hepatocarcinoma diagnosis kit combined with DNA logic gate and aptamer sequencing

The application discloses a liver cancer diagnosis kit combined with DNA logic gate and nucleic acid aptamer sequencing, belongs to the field of diagnosis kits, and particularly relates to a double-stranded "and gate" logic operation composed of DNA sequences of cT1, cT2, cT35 and I, and an amplification reagent containing S-II, W, F, F-Cy5, M1 and M1-Cy3 based on entropy-driven amplification reaction. After PBMC is extracted from whole blood, the kit can perform logic analysis on whether target proteins corresponding to nucleic acid aptamers Apt51, GR-30 and IBA are simultaneously present on the PBMC, so that early screening of liver cancer is realized. The specific target of liver cancer patients found by high-throughput sequencing of nucleic acid aptamers can be effectively distinguished from healthy people and cancer patients by the kit.
Owner:HANGZHOU INSTITUTE OF MEDICAL SCIENCES CHINESE ACADEMY OF SCIENCES